Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Validation of a blood protein signature for non-small cell lung cancer

Mehan, MR and Williams, SA and Siegfried, JM and Bigbee, WL and Weissfeld, JL and Wilson, DO and Pass, HI and Rom, WN and Muley, T and Meister, M and Franklin, W and Miller, YE and Brody, EN and Ostroff, RM (2014) Validation of a blood protein signature for non-small cell lung cancer. Clinical Proteomics, 11 (1). ISSN 1542-6416

Published Version
Available under License : See the attached license file.

Download (735kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Background: CT screening for lung cancer is effective in reducing mortality, but there are areas of concern, including a positive predictive value of 4% and development of interval cancers. A blood test that could manage these limitations would be useful, but development of such tests has been impaired by variations in blood collection that may lead to poor reproducibility across populations. Results: Blood-based proteomic profiles were generated with SOMAscan technology, which measured 1033 proteins. First, preanalytic variability was evaluated with Sample Mapping Vectors (SMV), which are panels of proteins that detect confounders in protein levels related to sample collection. A subset of well collected serum samples not influenced by preanalytic variability was selected for discovery of lung cancer biomarkers. The impact of sample collection variation on these candidate markers was tested in the subset of samples with higher SMV scores so that the most robust markers could be used to create disease classifiers. The discovery sample set (n = 363) was from a multi-center study of 94 non-small cell lung cancer (NSCLC) cases and 269 long-term smokers and benign pulmonary nodule controls. The analysis resulted in a 7-marker panel with an AUC of 0.85 for all cases (68% adenocarcinoma, 32% squamous) and an AUC of 0.93 for squamous cell carcinoma in particular. This panel was validated by making blinded predictions in two independent cohorts (n = 138 in the first validation and n = 135 in the second). The model was recalibrated for a panel format prior to unblinding the second cohort. The AUCs overall were 0.81 and 0.77, and for squamous cell tumors alone were 0.89 and 0.87. The estimated negative predictive value for a 15% disease prevalence was 93% overall and 99% for squamous lung tumors. The proteins in the classifier function in destruction of the extracellular matrix, metabolic homeostasis and inflammation. Conclusions: Selecting biomarkers resistant to sample processing variation led to robust lung cancer biomarkers that performed consistently in independent validations. They form a sensitive signature for detection of lung cancer, especially squamous cell histology. This non-invasive test could be used to improve the positive predictive value of CT screening, with the potential to avoid invasive evaluation of nonmalignant pulmonary nodules.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Mehan, MR
Williams, SA
Siegfried, JMjsiegfr@pitt.eduJSIEGFR
Bigbee, WL
Weissfeld, JL
Wilson, DOwilsond@pitt.eduWILSOND
Pass, HI
Rom, WN
Muley, T
Meister, M
Franklin, W
Miller, YE
Brody, EN
Ostroff, RM
Centers: Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date: 1 August 2014
Date Type: Publication
Journal or Publication Title: Clinical Proteomics
Volume: 11
Number: 1
DOI or Unique Handle: 10.1186/1559-0275-11-32
Schools and Programs: School of Public Health > Epidemiology
Refereed: Yes
ISSN: 1542-6416
Date Deposited: 19 Sep 2016 15:24
Last Modified: 27 Mar 2021 10:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item